Aegerion postpones IPO

Aegerion Pharmaceuticals, a specialty US drugmaker focused on the treatment of cardiovascular and metabolic diseases, says it has postponed its initial public offering.

"The company has decided not to move forward with the proposed IPO at this time," said Jerry Wisler, chief executive, adding: "the postponement of Aegerion's IPO has no impact on ongoing clinical programs, which continue to progress as scheduled. Aegerion is well capitalized and remains on track to achieve all projected clinical milestones."